BioVie: Treating Alzheimer's, Parkinson's potentially reversing the aging process

Dec. 7, 2022 |  Learn More About BioVie




BioVie president and CEO Cuong Do discusses the positive results of its Parkinson's and Alzheimer's phase 2 trials and explains how its NE3107 drug could reverse the biological clock on 'Varney & Co.'



"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President, NASDAQ Stock Market